Evidence map›Paper›PMID 41457564›Full record

Trial reportCancer science2026

Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK-Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan.

Tetsuya Mori, Akiko Kada, Tomoo Osumi, Daisuke Tomizawa, Yuhki Koga, Reiji Fukano, Kengo Takeuchi, Ukihide Tateishi, Osamu Miyazaki, Ryuta Asada and 3 more

Abstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tetsuya MoriDepartment of Pediatrics, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.ORCID https://orcid.org/0000-0002-9180-3196
Akiko KadaClinical Research Center, NHO Nagoya Medical Center, Nagoya, Aichi, Japan.
Tomoo OsumiChildren's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Daisuke TomizawaChildren's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Yuhki KogaDepartment of Pediatrics, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Reiji FukanoDepartment of Pediatrics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.ORCID https://orcid.org/0000-0002-4087-3426
Kengo TakeuchiDivision of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID https://orcid.org/0000-0002-1599-5800
Ukihide TateishiDepartment of Diagnostic Radiology and Nuclear Medicine, Institute of Science Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-6548-8698
Osamu MiyazakiDepartment of Radiology, National Center for Child Health and Development, Tokyo, Japan.
Ryuta AsadaDepartment of Medical Research and Development Strategy, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Akiko M SaitoClinical Research Center, NHO Nagoya Medical Center, Nagoya, Aichi, Japan.
Kei FukuharaDepartment of Clinical Research, Pfizer R&D Japan, Tokyo, Japan.
Masahiro SekimizuDepartment of Pediatrics, NHO Nagoya Medical Center, Nagoya, Aichi, Japan.

Funding

Clinical Research Collaboration, PfizerHealth Labour Sciences Research 201438110AMinistry of Health, Labour and Welfare 18lk0201046h0003
6 · The paper itself

Abstract

Clinical development of crizotinib in children with ALK-positive anaplastic large cell lymphoma (ALCL) was advanced in the US but not in Japan. The objectives of phase 1 part of a clinical study in Japan were to assess the safety and pharmacokinetics and determine the recommended phase 2 dose (RP2D) of crizotinib in children with relapsed/refractory (R/R) ALK-positive ALCL or neuroblastoma (NB). Two dose levels (165 and 280 mg/m

Indexed as

Anaplastic Lymphoma KinaseAntineoplastic AgentsCrizotinibLymphoma, Large-Cell, AnaplasticNeuroblastomaProtein Kinase InhibitorsAdolescentChildChild, PreschoolDrug Resistance, NeoplasmFemaleHumansJapanMaleNeoplasm Recurrence, LocalALK protein, humanAnaplastic Lymphoma KinaseAntineoplastic AgentsCrizotinibProtein Kinase InhibitorsALK inhibitoranaplastic large cell lymphomachildrenCrizotinibrelapse

Identifiers

PMID41457564
PMCPMC12951090

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.